This Article Full Text Full Text (PDF) All Versions of this Article: 39/4/1228    most recent STROKEAHA.107.496729v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hills, N. K. Articles by Johnston, S. C. Search for Related Content PubMed PubMed Citation Articles by Hills, N. K. Articles by Johnston, S. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Medline Plus Health Information Blood Thinners Stroke Transient Ischemic Attack Related Collections Secondary prevention Antiplatelets

(Stroke. 2008;39:1228.)
© 2008 American Heart Association, Inc.

Original Contributions

Trends in Usage of Alternative Antiplatelet Therapy After Stroke and Transient Ischemic Attack

From the Departments of Neurology (N.K.H., S.C.J.) and Epidemiology and Biostatistics (S.C.J.), University of California, San Francisco.

Correspondence and reprint requests to S. Claiborne Johnston, MD, PhD, Department of Neurology, 505 Parnassus Ave, M-798, Box 0114, University of California, San Francisco, CA 94143-0114. E-mail clay.johnston{at}ucsfmedctr.org

Background and Purpose— The effects of alternative antiplatelet agents such as clopidogrel and dipyridamole have been studied in clinical trials and heavily marketed. Because public data on their usage are limited, we examined trends in their prescription after stroke and transient ischemic attack to assess the impact of marketing and trial results.

Methods— Between 2001 and 2005, 85 US hospitals prospectively enrolled all patients admitted with ischemic stroke or transient ischemic attack into a registry designed for quality improvement (Ethos). Data on rates of antiplatelet medication usage at discharge were examined over time, and trends were evaluated by the Mantel-Haenszel test.

Results— Among 18 020 patients included during the 4-year period, 89% were discharged on antithrombotic medication. Between the first quarter of 2001 and the first quarter of 2004, prescription of clopidogrel-aspirin doubled (P<0.0001 for trend), coincident with publication of results from CURE and CREDO showing efficacy in patients with acute coronary syndromes. Monotherapy with aspirin or clopidogrel decreased concomitantly, and use of dipyridamole-aspirin remained constant. After an increased bleeding risk was reported in the clopidogrel-aspirin arm of the MATCH trial, use of the combination decreased sharply from 31.5% in the first quarter of 2004 to 12.8% in the first quarter of 2005 (P<0.0001), while an increase was seen in the use of clopidogrel alone (7.6% to 12.8%, P=0.03) and dipyridamole-aspirin (7.4% to 20.2%, P<0.0001).

Conclusions— Clopidogrel and dipyridamole-aspirin are used frequently after stroke or transient ischemic attack. Use of clopidogrel-aspirin was common in patients with recent ischemic stroke before the publication of MATCH, after which rates dramatically declined and use of dipyridamole-aspirin and clopidogrel alone increased.

Key Words: antiplatelet agents • antithrombotics • stroke • transient ischemic attack • clinical trials • secondary prevention